Brokers Offer Predictions for BrainsWay Ltd.’s Q2 2024 Earnings (NASDAQ:BWAY)

BrainsWay Ltd. (NASDAQ:BWAYFree Report) – Investment analysts at HC Wainwright upped their Q2 2024 earnings estimates for BrainsWay in a report released on Wednesday, June 5th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.00 per share for the quarter, up from their prior forecast of ($0.01). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for BrainsWay’s Q3 2024 earnings at $0.01 EPS, Q4 2024 earnings at $0.01 EPS and FY2025 earnings at $0.03 EPS.

BrainsWay (NASDAQ:BWAYGet Free Report) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. The company had revenue of $9.03 million for the quarter, compared to analyst estimates of $8.40 million. BrainsWay had a negative return on equity of 3.98% and a negative net margin of 4.83%. During the same quarter in the prior year, the company posted ($0.12) EPS.

Separately, Oppenheimer lifted their price target on BrainsWay from $10.00 to $11.00 and gave the company an “outperform” rating in a report on Thursday, May 9th.

Check Out Our Latest Stock Analysis on BWAY

BrainsWay Trading Down 8.2 %

BrainsWay stock opened at $6.50 on Friday. The stock has a fifty day moving average price of $5.49 and a 200 day moving average price of $5.96. BrainsWay has a 52 week low of $2.01 and a 52 week high of $7.61. The firm has a market capitalization of $108.23 million, a P/E ratio of -50.00 and a beta of 1.23.

Institutional Trading of BrainsWay

Several institutional investors have recently made changes to their positions in BWAY. Tucker Asset Management LLC boosted its holdings in BrainsWay by 1,686.9% in the fourth quarter. Tucker Asset Management LLC now owns 5,450 shares of the company’s stock valued at $35,000 after acquiring an additional 5,145 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of BrainsWay during the 3rd quarter worth about $28,000. Quadrature Capital Ltd purchased a new stake in shares of BrainsWay during the 4th quarter worth about $70,000. Virtu Financial LLC acquired a new stake in BrainsWay during the 1st quarter worth approximately $60,000. Finally, Jump Financial LLC purchased a new position in BrainsWay in the fourth quarter valued at approximately $207,000. 30.11% of the stock is owned by hedge funds and other institutional investors.

About BrainsWay

(Get Free Report)

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

Further Reading

Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with's FREE daily email newsletter.